Chordia Therapeutics (TSE:190A) ROCE % : -166.37% (As of Aug. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Chordia Therapeutics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Chordia Therapeutics's annualized ROCE % for the quarter that ended in Aug. 2024 was -166.37%.

Chordia Therapeutics ROCE % Historical Data

The historical data trend for Chordia Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chordia Therapeutics ROCE % Chart

Chordia Therapeutics Annual Data

Trend

Aug21

Aug22

Aug23

Aug24

ROCE %

-33.44

-57.77

4.83

-41.59

Chordia Therapeutics Quarterly Data
	Aug21	Aug22	Aug23	Aug24
ROCE %	-133.78	-231.08	19.33	-166.37

Chordia Therapeutics ROCE % Calculation

Chordia Therapeutics's annualized ROCE % for the fiscal year that ended in Aug. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Aug. 2024 )		(A: Aug. 2023 )		(A: Aug. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Aug. 2024 )		(A: Aug. 2023 )		(A: Aug. 2024 )
	=	-1801.395	/	( ( (4909.123 - 408.241)	+	(4632.37 - 471.072) )	/ 2 )
	=	-1801.395	/	( (4500.882	+	4161.298)	/ 2 )
	=	-1801.395	/	4331.09
	=	-41.59 %

Chordia Therapeutics's ROCE % of for the quarter that ended in Aug. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Aug. 2024 )		(Q: Aug. 2023 )		(Q: Aug. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Aug. 2024 )		(Q: Aug. 2023 )		(Q: Aug. 2024 )
	=	-7205.58	/	( ( (4909.123 - 408.241)	+	(4632.37 - 471.072) )	/ 2 )
	=	-7205.58	/	( ( 4500.882	+	4161.298 )	/ 2 )
	=	-7205.58	/	4331.09
	=	-166.37 %

(1) Note: The EBIT data used here is four times the quarterly (Aug. 2024) EBIT data.

Chordia Therapeutics (TSE:190A) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Chordia Therapeutics ROCE % Related Terms

Thank you for viewing the detailed overview of Chordia Therapeutics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Chordia Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chordia Therapeutics Inc (TSE:190A) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

2-26-1 Muraoka-Higashi, Kanagawa, Fujisawa, JPN, 251-0012

Website

https://www.chordiatherapeutics.com

Chordia Therapeutics Inc is a bio-venture company specializing in cancer research and development. Its mission is to deliver first-in-class cancer drugs to patients. It is a clinical-stage biotech company engaged in researching and developing novel therapies for cancers with high unmet medical needs.

Chordia Therapeutics Headlines

No Headlines